Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey I Shapiro

Showing results (11-20 of 277) with videos related to

Pageof 28
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic BiomarkersErik S Knudsen, Geoffrey I Shapiro, Khandan Keyomarsi
Cancer Research|January 7, 2006
AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9Dongpo Cai, Kate F Byth, Geoffrey I Shapiro
Drugs|November 22, 2014
The biology and clinical development of MEK inhibitors for cancerJason J Luke, Patrick A Ott, Geoffrey I Shapiro
Breast Care (Basel, Switzerland)|August 6, 2016
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast CancerRomualdo Barroso-Sousa, Geoffrey I Shapiro, Sara M Tolaney
Cancer Research|September 20, 2006
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cellsDongpo Cai, Vaughan M Latham, Xinxin Zhang, et al.
Cancer Research|July 19, 2005
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsTakeshi Shimamura, April M Lowell, Jeffrey A Engelman, et al.
Cancer Discovery|October 15, 2015
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerPanagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, et al.
Molecular Cell|May 28, 2020
Biomarker-Guided Development of DNA Repair InhibitorsJames M Cleary, Andrew J Aguirre, Geoffrey I Shapiro, et al.
Frontiers in Bioscience (Landmark Edition)|June 11, 2013
Poly(ADP-ribose) polymerase inhibitors as cancer therapyJohn F Hilton, Matthew J Hadfield, Minh-Thu Tran, et al.
Journal of the National Cancer Institute|June 26, 2014
Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experienceSuzanne E Dahlberg, Geoffrey I Shapiro, Jeffrey W Clark, et al.
Pageof 28

Showing results (11-20 of 277) with videos related to

Sort By:
Pageof 28
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic BiomarkersErik S Knudsen, Geoffrey I Shapiro, Khandan Keyomarsi
Cancer Research|January 7, 2006
AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9Dongpo Cai, Kate F Byth, Geoffrey I Shapiro
Drugs|November 22, 2014
The biology and clinical development of MEK inhibitors for cancerJason J Luke, Patrick A Ott, Geoffrey I Shapiro
Breast Care (Basel, Switzerland)|August 6, 2016
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast CancerRomualdo Barroso-Sousa, Geoffrey I Shapiro, Sara M Tolaney
Cancer Research|September 20, 2006
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cellsDongpo Cai, Vaughan M Latham, Xinxin Zhang, et al.
Cancer Research|July 19, 2005
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsTakeshi Shimamura, April M Lowell, Jeffrey A Engelman, et al.
Cancer Discovery|October 15, 2015
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerPanagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, et al.
Molecular Cell|May 28, 2020
Biomarker-Guided Development of DNA Repair InhibitorsJames M Cleary, Andrew J Aguirre, Geoffrey I Shapiro, et al.
Frontiers in Bioscience (Landmark Edition)|June 11, 2013
Poly(ADP-ribose) polymerase inhibitors as cancer therapyJohn F Hilton, Matthew J Hadfield, Minh-Thu Tran, et al.
Journal of the National Cancer Institute|June 26, 2014
Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experienceSuzanne E Dahlberg, Geoffrey I Shapiro, Jeffrey W Clark, et al.
Pageof 28